| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
381,510,000 |
| Market
Cap: |
169.20(M) |
| Last
Volume: |
4,513,016 |
Avg
Vol: |
4,500,422 |
| 52
Week Range: |
$0.4435 - $2.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
500,000 |
525,000 |
525,000 |
525,000 |
| Total Buy Value |
$324,050 |
$343,050 |
$343,050 |
$343,050 |
| Total People Bought |
1 |
2 |
2 |
2 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hirsch Susan B |
Director |
– • – |
2022-04-01 |
4 |
A |
$2.75 |
$18,751 |
D/D |
6,811 |
28,382 |
|
- |
|
| Klaskin Christine M |
PFO & PAO |
• – – |
2022-02-02 |
4 |
A |
$2.51 |
$74,263 |
D/D |
29,587 |
122,643 |
|
- |
|
| Oday Steven J |
Chief Medical Officer |
• – – |
2022-02-02 |
4 |
A |
$2.51 |
$255,222 |
D/D |
101,682 |
163,003 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2022-02-02 |
4 |
A |
$2.51 |
$594,898 |
D/D |
237,011 |
1,007,784 |
|
- |
|
| Oday Steven J |
Chief Medical Officer |
• – – |
2022-01-06 |
4 |
S |
$3.06 |
$118,346 |
D/D |
(38,679) |
61,321 |
|
45% |
|
| Oday Steven J |
Chief Medical Officer |
• – – |
2022-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
100,000 |
100,000 |
|
- |
|
| Hirsch Susan B |
Director |
– • – |
2022-01-03 |
4 |
A |
$4.01 |
$18,755 |
D/D |
4,677 |
21,571 |
|
- |
|
| Hirsch Susan B |
Director |
– • – |
2021-10-01 |
4 |
A |
$5.76 |
$18,760 |
D/D |
3,257 |
16,894 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2021-09-13 |
4 |
S |
$6.50 |
$533,696 |
D/D |
(82,107) |
770,773 |
|
58% |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2021-09-13 |
4 |
OE |
$3.36 |
$400,438 |
D/D |
119,178 |
852,880 |
|
- |
|
| Klaskin Christine M |
PFO & PAO |
• – – |
2021-09-10 |
4 |
S |
$6.50 |
$72,280 |
D/D |
(11,120) |
93,056 |
|
59% |
|
| Klaskin Christine M |
PFO & PAO |
• – – |
2021-09-10 |
4 |
OE |
$3.36 |
$55,652 |
D/D |
16,563 |
104,176 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2021-07-02 |
4 |
A |
$5.52 |
$14,788 |
D/D |
2,679 |
733,702 |
|
- |
|
| Hirsch Susan B |
Director |
– • – |
2021-07-01 |
4 |
A |
$3.82 |
$18,749 |
D/D |
4,908 |
13,637 |
|
- |
|
| Buell Jennifer |
COO and President |
• – – |
2021-06-30 |
4 |
A |
$5.49 |
$58,178 |
D/D |
10,597 |
127,091 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2021-06-18 |
4 |
A |
$5.26 |
$14,791 |
D/D |
2,812 |
610,023 |
|
- |
|
| Wright Timothy |
Director |
– • – |
2021-06-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,853 |
50,391 |
|
- |
|
| Jeynes-Ellis Allison M |
Director |
– • – |
2021-06-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,853 |
66,176 |
|
- |
|
| Wiinberg Ulf |
Director |
– • – |
2021-06-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,853 |
99,063 |
|
- |
|
| Corvese Brian |
Director |
– • – |
2021-06-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,471 |
92,085 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2021-06-04 |
4 |
A |
$4.03 |
$14,790 |
D/D |
3,670 |
607,211 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2021-05-21 |
4 |
A |
$4.19 |
$14,791 |
D/D |
3,530 |
603,541 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2021-05-07 |
4 |
A |
$3.07 |
$14,788 |
D/D |
4,817 |
600,011 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2021-04-23 |
4 |
A |
$3.05 |
$14,789 |
D/D |
4,849 |
595,194 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2021-04-09 |
4 |
A |
$2.79 |
$12,936 |
D/D |
4,645 |
590,345 |
|
- |
|
186 Records found
|
|
Page 2 of 8 |
|
|
